Back to top

RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial

Revolution Medicines, Inc. ($RVMD) announced an update on their ongoing clinical study. Revolution Medicines, Inc. (RVMD) is running a Phase 3 stud...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Revolution Medicines, Inc. (RVMD)